Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are:
- To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with
moderate to severe chronic plaque psoriasis.
- To evaluate the efficacy of three doses levels of MT-1303 in subjects with moderate to
severe chronic plaque psoriasis compared to placebo after 16 weeks of treatment on
Psoriasis Area and Severity Index (PASI).